FDA.reportPublic FDA data

amikacin liposomal 590 MG in 8.4 ML Inhalation Suspension

RxCUI
2059184
RxNorm name
amikacin liposomal 590 MG in 8.4 ML Inhalation Suspension
Display name
amikacin liposomal 590 MG in 8.4 ML Inhalation Suspension
Full name
amikacin liposomal 590 MG in 8.4 ML Inhalation Suspension
Term type
PSN
Status
DailyMed mapping
Updated
2026-06-04 23:38:56

RxNav Current And Historical NDCs#

RxNav current and historical NDC rows page 1 of 1 · 0 matching rows.

No records found.

UNII Substances#

UNII substance links page 1 of 1 · 0 matching rows.

No records found.

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 1 matching rows.

Brand, Generic, Manufacturer table
BrandGenericManufacturerSPL set IDEffective dateAvailable safety fieldsJoin
ARIKAYCEAMIKACINInsmed Incorporated499ab990-2b21-474f-aaba-d86388965f402026-08-04Boxed warning, Warnings, Adverse reactionsExact identifier
rxcui: 2059184

DailyMed RxNorm Mappings#

unique DailyMed labels mapped to this RxNorm concept page 1 of 1 · 1 matching rows.

Set ID, RxNorm mappings, Terms table
Set IDRxNorm mappingsTermsSPL versionLabelEffective
499ab990-2b21-474f-aaba-d86388965f40amikacin liposomal 590 MG in 8.4 ML Inhalation Suspension [PSN] · amikacin liposomal 70.3 MG/ML Inhalation Suspension [SCD] · amikacin liposomal 590 MG per 8.4 ML Inhalation Suspension [SY]314These highlights do not include all the information needed to use ARIKAYCE safely and effectively. See full prescribing information for ARIKAYCE. ARIKAYCE ® (amikacin liposome inhalation suspension), for oral inhalation use Initial U.S. Approval: 2018 LIMITED POPULATION20251229